| Literature DB >> 29800237 |
Roxana Loperena1, Justin P Van Beusecum2, Hana A Itani2, Noah Engel3, Fanny Laroumanie2, Liang Xiao2, Fernando Elijovich2, Cheryl L Laffer2, Juan S Gnecco4, Jonathan Noonan5, Pasquale Maffia5,6,7, Barbara Jasiewicz-Honkisz8,9, Marta Czesnikiewicz-Guzik6, Tomasz Mikolajczyk8,9, Tomasz Sliwa8,9, Sergey Dikalov2, Cornelia M Weyand10, Tomasz J Guzik6, David G Harrison1,2.
Abstract
Aims: Monocytes play an important role in hypertension. Circulating monocytes in humans exist as classical, intermediate, and non-classical forms. Monocyte differentiation can be influenced by the endothelium, which in turn is activated in hypertension by mechanical stretch. We sought to examine the role of increased endothelial stretch and hypertension on monocyte phenotype and function. Methods and results: Human monocytes were cultured with confluent human aortic endothelial cells undergoing either 5% or 10% cyclical stretch. We also characterized circulating monocytes in normotensive and hypertensive humans. In addition, we quantified accumulation of activated monocytes and monocyte-derived cells in aortas and kidneys of mice with Angiotensin II-induced hypertension. Increased endothelial stretch enhanced monocyte conversion to CD14++CD16+ intermediate monocytes and monocytes bearing the CD209 marker and markedly stimulated monocyte mRNA expression of interleukin (IL)-6, IL-1β, IL-23, chemokine (C-C motif) ligand 4, and tumour necrosis factor α. STAT3 in monocytes was activated by increased endothelial stretch. Inhibition of STAT3, neutralization of IL-6 and scavenging of hydrogen peroxide prevented formation of intermediate monocytes in response to increased endothelial stretch. We also found evidence that nitric oxide (NO) inhibits formation of intermediate monocytes and STAT3 activation. In vivo studies demonstrated that humans with hypertension have increased intermediate and non-classical monocytes and that intermediate monocytes demonstrate evidence of STAT3 activation. Mice with experimental hypertension exhibit increased aortic and renal infiltration of monocytes, dendritic cells, and macrophages with activated STAT3. Conclusions: These findings provide insight into how monocytes are activated by the vascular endothelium during hypertension. This is likely in part due to a loss of NO signalling and increased release of IL-6 and hydrogen peroxide by the dysfunctional endothelium and a parallel increase in STAT activation in adjacent monocytes. Interventions to enhance bioavailable NO, reduce IL-6 or hydrogen peroxide production or to inhibit STAT3 may have anti-inflammatory roles in hypertension and related conditions.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29800237 PMCID: PMC6106108 DOI: 10.1093/cvr/cvy112
Source DB: PubMed Journal: Cardiovasc Res ISSN: 0008-6363 Impact factor: 10.787
Clinical characteristics of patients studied for comparison of circulating monocytes (n=132)
| NT | HTN well controlled | HTN poorly controlled | ||
|---|---|---|---|---|
| Age | 58.1 ± 12 | 59.8 ± 10.9 | 62 ± 10 | NS |
| Race (W/B) | 20/0 | 52/0 | 60/0 | – |
| Sex (M/F) | 13 Jul | 24/28 | 27/33 | NS |
| BMI | 26.1 ± 2.7 | 28.8 ± 5.7 | 28.0 ± 4.7 | NS |
| SBP | 120 ± 10 | 127 ± 8 | 147 ± 13 | <0.001 |
| DBP | 77 ± 10 | 81 ± 7 | 90 ± 8 | <0.001 |
| Cholesterol | 5.6 ± 1.4 | 5.2 ± 1.5 | 5.5 ± 1.3 | NS |
| Smoking | 20 May | 16/52 | 16/60 | NS |
| Hypercholesterolemia | 20 Nov | 35/52 | 48/60 | NS |
| Medications ( | Pearson | |||
| ACEi | 3 | 41 | 55 | <0.002 |
| CCB | 1 | 14 | 36 | <0.01 |
| BB | 5 | 33 | 39 | 0.4 |
| Diuretic | 1 | 25 | 50 | <0.001 |
| ARB | 0 | 5 | 5 | 0.7 |
| α1B | 0 | 2 | 12 | <0.02 |
| Statin | 8 | 26 | 31 | 0.8 |
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin AT1-receptor blocker; BB, beta-blocker; α1B, alpha-1 adrenergic receptor antagonist; CCB + BB, nifedipine and metoprolol; CCB + α1B, amlodipine and doxazosin.
Demographics of patients studied for analysis of phospho-STAT in circulating monocytes
| Normotensive | Hypertensive | ||
|---|---|---|---|
| 15 | 12 | ||
| Age (years) | 44.8±3.9 | NS | 51.3±2.6 |
| Race (W/B) | 15/0 | NS | 3 Sep |
| Gender (F/M) | 4-Nov | NS | 3 Sep |
| BMI (Kg/m2) | 26.6±1.3 | <0.03 | 34.7±2.9 |
| SBP (mmHg) | 110.8±3.7 | <0.00003 | 140.5±4.1 |
| DBP (mmHg) | 64.4±1.6 | <0.003 | 78.7±3.6 |
| Drug Rx | |||
| None | 15 | 2 | |
| ACEi | 0 | 4 | |
| ARB | 0 | 1 | |
| HCTZ+ACEi | 0 | 2 | |
| HCTZ+ARB | 0 | 1 | |
| CCB+BB | 0 | 1 | |
| CCB+α1B | 0 | 1 |
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin AT1-receptor blocker; HCTZ, hydrochlorothiazide; BB, beta-blocker; α1B, peripheral alpha-1 adrenergic receptor antagonist; CCB + BB, nifedipine and metoprolol; CCB + α1B, amlodipine and doxazosin.